132 related articles for article (PubMed ID: 34621310)
1. LncRNA LUCAT1 as a Plasma Biomarker for Assessing Disease Activity in Adult Patients with Crohn's Disease.
Kuai XY; Yu SY; Cui XF; Zhao XJ; Mao XQ; Yu Y; Hu T; Zhang HJ; Zhou CL
Gastroenterol Res Pract; 2021; 2021():5557357. PubMed ID: 34621310
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of fecal calprotectin for evaluating disease activity in patients with Crohn's disease.
Li J; Xu M; Qian W; Ling F; Chen Y; Li S; Cheng Y; Zhu L
Front Physiol; 2023; 14():1186665. PubMed ID: 37324392
[No Abstract] [Full Text] [Related]
3. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between contrast-enhanced ultrasound parameters and Crohn's disease activity].
Zhang YY; Yuan T; Wang CW; Wang L; Zhang HJ; Wang YL
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):427-432. PubMed ID: 37032139
[No Abstract] [Full Text] [Related]
5. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
6. Long Noncoding RNA Antisense Noncoding RNA in the INK4 Locus Correlates With Risk, Severity, Inflammation and Infliximab Efficacy in Crohn's Disease.
Ge Q; Dong Y; Lin G; Cao Y
Am J Med Sci; 2019 Feb; 357(2):134-142. PubMed ID: 30665494
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease.
E Penna FGC; Rosa RM; da Cunha PFS; de Souza SCS; de Abreu Ferrari ML
BMC Gastroenterol; 2020 Feb; 20(1):35. PubMed ID: 32054445
[TBL] [Abstract][Full Text] [Related]
8. Simple Enterographic Activity Score for Crohn's Disease: comparison with endoscopic, biochemical, and clinical findings.
Eder P; Katulska K; Lykowska-Szuber L; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K
Pol Arch Med Wewn; 2013; 123(7-8):378-85. PubMed ID: 23778300
[TBL] [Abstract][Full Text] [Related]
9. Plateletcrit: a sensitive biomarker for evaluating disease activity in Crohn's disease with low hs-CRP.
Tang J; Gao X; Zhi M; Zhou HM; Zhang M; Chen HW; Yang QF; Liang ZZ
J Dig Dis; 2015 Mar; 16(3):118-24. PubMed ID: 25565427
[TBL] [Abstract][Full Text] [Related]
10. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
Schaffer T; Schoepfer AM; Seibold F;
J Crohns Colitis; 2014 Sep; 8(9):1125-32. PubMed ID: 24636141
[TBL] [Abstract][Full Text] [Related]
11. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
[TBL] [Abstract][Full Text] [Related]
12. Can the simplified magnetic resonance index of activity be used to evaluate the degree of activity in Crohn's disease?
Tao Y; Li H; Xu H; Tang W; Fan G; Yang X
BMC Gastroenterol; 2021 Oct; 21(1):409. PubMed ID: 34711180
[TBL] [Abstract][Full Text] [Related]
13. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
14. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
[TBL] [Abstract][Full Text] [Related]
15. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
16. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
[TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
18. [Association of Breg cells and Treg cells with the clinical effects of Infliximab in the treatment of Chinese patients with Crohn's disease].
Lin QR; Xia XP; Cai XN; Hu DY; Shao XX; Xia SL; Jiang Y
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3303-3308. PubMed ID: 33202491
[No Abstract] [Full Text] [Related]
19. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
[TBL] [Abstract][Full Text] [Related]
20. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin.
Zubin G; Peter L
Inflamm Bowel Dis; 2015 Jun; 21(6):1386-91. PubMed ID: 25851564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]